Literature DB >> 22153126

Advances in ovarian cancer disease control.

Robert A Burger.   

Abstract

Entities:  

Mesh:

Year:  2012        PMID: 22153126     DOI: 10.1016/j.ygyno.2011.11.011

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


× No keyword cloud information.
  4 in total

Review 1.  Synthetic strategies to terpene quinones/hydroquinones.

Authors:  Marina Gordaliza
Journal:  Mar Drugs       Date:  2012-02-14       Impact factor: 6.085

2.  Ruxolitinib synergistically enhances the anti-tumor activity of paclitaxel in human ovarian cancer.

Authors:  Ernest S Han; Wei Wen; Thanh H Dellinger; Jun Wu; Selena A Lu; Richard Jove; John H Yim
Journal:  Oncotarget       Date:  2018-01-31

Review 3.  Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer.

Authors:  Theresa A Lawrie; Brett A Winter-Roach; Pauline Heus; Henry C Kitchener
Journal:  Cochrane Database Syst Rev       Date:  2015-12-17

4.  A novel angiopoietin-2 selective fully human antibody with potent anti-tumoral and anti-angiogenic efficacy and superior side effect profile compared to Pan-Angiopoietin-1/-2 inhibitors.

Authors:  Markus Thomas; Yvonne Kienast; Werner Scheuer; Monika Bähner; Klaus Kaluza; Christian Gassner; Frank Herting; Ulrich Brinkmann; Stefan Seeber; Anita Kavlie; Martin Welschof; Stefan Ries; K Michael Weidner; Jörg T Regula; Christian Klein
Journal:  PLoS One       Date:  2013-02-06       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.